Abstract Infective endocarditis (IE) is a serious form of infection with a high mortality. Medical management can be a challenge because of organ dysfunction, lack of clinical response or allergy to the recommended antibiotics.
Introduction
Despite advances in the diagnosis, surgical and medical management of infective endocarditis (IE), it continues to be associated with a high rate of morbidity and mortality [1] . The management of IE can be a challenge because of therapeutic failure with the recommended standard antibiotics [2] , as well as the need for prolonged duration of therapy, during which allergic reactions or toxicity to the antibiotic(s) are often encountered. Moreover, combination therapy with aminoglycosides is often unsuitable due to the presence of resistance in the causative organism or impaired renal function in the patient. Vancomycin is mostly recommended as an alternative agent to the β-lactam group of agents in the treatment of IE [2] [3] [4] . However, there is increasing concern regarding the efficacy of vancomycin in the recent literature [5, 6] . Despite this, there is currently a lack of clear guidance on the management of patients with therapeutic failure or allergy associated with vancomycin/glycopeptides. As the options on alternative antibiotics are limited, there is a need for new agents in the treatment of IE.
Daptomycin is a novel lipopeptide antibiotic with a unique mechanism of action against Gram-positive bacteria that is rapidly bactericidal in vitro [7] . It has been shown to be effective in experimental models of endocarditis as well as in clinical studies [7] [8] [9] .
Objective The aim was to report our experience on the use of daptomycin in complicated cases of IE through a prospective observational study.
Methods
An observational study was carried out in a 1,200-bed tertiary care and referral centre for adult cardiology (including cardiac transplantation) located in the West Midlands, UK. Cases of IE were identified prospectively following a positive blood culture report and consultations by the Cardiac Unit over a one-year period from 1 October 2008 to 30 September 2009. Blood cultures were processed by the automated blood culture system BacT/ALERT 3D (bioMerieux SA, Marcy I'Etoile, France). The isolates were identified by the standard method. Antimicrobial sensitivity was performed by the automated method using Vitek 2 (bioMerieux, Marcy I'Etoile, France). The minimum inhibitory concentration (MIC) for penicillin and ampicillin was performed on all streptococcal and enterococcal isolates, respectively, by the Etest (AB Biodisk, Solna, Sweden). High-level aminoglycoside sensitivity was performed by the disc sensitivity testing using the BSAC method (BSAC standardized disc susceptibility testing method, version 8). Daptomycin sensitivity was performed by the Etest according to the manufacturer's recommendation. Cases were followed up through routine ward visits during their hospital stay.
Indication for daptomycin use included all cases of IE where the medical therapy with the standard antibiotics [2] was considered to be ineffective or inappropriate as follows: lack of clinical response; failure of inflammatory markers of sepsis to fall; evidence of progression of IE (as revealed by echocardiography); existing history of allergy or development of allergic reaction/toxicity; detection of resistance to the standard antibiotics in the blood culture isolate. All cases of IE receiving daptomycin were recorded. Microbiological and relevant non-microbiological laboratory results were reviewed through the electronic microbiology laboratory system (Telepath) and the Patient Information and Prescribing System (PICS). Details of antibiotic therapy were recorded from the PICS. Subsequent blood cultures following the initiation of any type of antibiotic therapy (standard or daptomycin) were only collected when clinically indicated (lack of resolution or progression of clinical/laboratory markers of sepsis) according to routine practice. Follow up after discharge from the hospital was undertaken through discussion with the admitting team and the review of follow up notes (including laboratory results) of clinic appointment at a minimum period of 8 weeks from discharge. Further review was undertaken at a minimum period of 3 months after discharge through telephone contact with the respective general practitioners.
Definitions A diagnosis of IE was established according to the modified Duke criteria [10] . Success was defined as the resolution of clinical and laboratory features (inflammatory markers, i.e. C-reactive protein levels ,CRP) of sepsis and continuation of these findings for a minimum period of 8 weeks from the end of therapy. Relapse was defined as the reappearance of signs of sepsis following a period of clinical improvement in the absence of any other apparent cause and progressive disease as supported by echocardiography with or without repeat isolation of a causative organism from blood cultures.
Results
Clinical, microbiological and echocardiographic data on all of the eight patients receiving daptomycin are summarised in Table 1 . All patients received daptomycin as the secondor third-line therapy. The MIC of daptomycin for the available isolates are shown in Table 2 . CRP values in relation to daptomycin therapy are shown in Fig. 1 .
All isolates were obtained from the original blood cultures at the time of initial presentation. There was no repeat isolation of the causative organism from subsequent blood cultures obtained from patients with unresolving/ progressive clinical features of sepsis while continuing on the initial antibiotic therapy. One patient was excluded from the analysis as Streptococcus mitis isolated from the blood culture was noted to be resistant to daptomycin. Daptomycin therapy was, therefore, discontinued after 6 days.
Three patients (nos. 3, 4 and 6) were seen at other hospitals initially and transferred to our hospital within one week of presentation for surgical assessment. The remaining four patients were admitted to our institution directly. The number of sets of positive blood cultures varied from one to four sets. One patient had a single set of positive blood cultures with a Staphylococcus aureus isolate (S. aureus was also detected in the explanted mitral valve by 16S r DNA PCR amplification and sequencing) and the rest of the patients had ≥2 sets of positive blood cultures. Four each of native and prosthetic valves were affected.
Among the native valve endocarditis (NVE), two each of aortic and mitral valves were affected. Two patients (nos. 1 and 3) developed a severe allergic reaction to penicillin in addition to persistent clinical features of sepsis. One patient (no. 4) with persisting poor renal function had an isolate of enterococcus possessing high-level resistance to aminoglycosides (gentamicin and streptomycin). Monotherapy with amoxicillin was considered to be inappropriate in this case. Overall, daptomycin was administered either as combination therapy (six patients) or monotherapy (two patients).
Four patients had prosthetic valve endocarditis (PVE), of which two developed recurrences during the early postoperative period (having undergone valve replacement at our institution). One of the patients (no. 5) had aortic valve endocarditis of his transplanted heart and had radiological Initial antibiotics comprised clindamycin and rifampicin, aimed at the treatment of a post-operative retrosternal collection. The patientwas subsequently noted to have endocarditis when the above therapy was changed to daptomycin and rifampicin evidence of embolisation to the spleen, liver and to the common ileac artery prior to valve replacement. He developed further complications associated with recurrence of endocarditis in the newly implanted valve with extensive aortic root abscess and development of heart block within 2 weeks of surgery, ongoing sepsis and renal failure. He was not suitable for re-operation. He received vancomycin and rifampicin initially for 6 weeks without clinical improvement. Antibiotic therapy was then changed to linezolid, which was continued for 7 weeks. He improved temporarily but subsequently developed thrombocytopaenia, lactic acidosis, rising inflammatory markers and clinical features of sepsis. Evidence of persistent IE was supported by echocardiography. Linezolid therapy was changed to daptomycin. He improved on daptomycin therapy and was discharged home 6 months after admission. He completed daptomycin therapy as an outpatient, leading to a total of 8 months therapy. One other patient (no. 7) in the above group developed IE in a prosthetic mitral valve accompanied with allergic reaction to vancomycin and possibly to rifampicin within 2 weeks of surgery. Another patient (no. 4) received daptomycin in combination with amoxicillin as he failed to improve with combination therapy with aminoglycoside. Additionally, it was considered inappropriate to continue the use of aminoglycoside in the presence of persistent poor renal function. The remaining patient (no. 8) in this group had a history of serious allergy to penicillin. She initially received clindamycin and rifampicin for surgical site infection and associated retrosternal collection due to S. aureus in the early post-operative period. Antibiotic therapy was changed to daptomycin following a transoesophageal echocardiography, which revealed vegetation on the recently implanted (at 2 weeks of surgery) aortic valve. Daptomycin therapy was continued as clinical progress associated with the resolution of inflammatory markers of sepsis was evident (Fig. 1) .
A successful outcome was documented in all of the eight patients, at a minimum follow up period of 8 weeks and at 3 month after the end of therapy. There was no report of relapse of endocarditis. No evidence of adverse events, including elevation of creatine kinase, was noted in any of the patients during daptomycin therapy.
Discussion
For several years, there have been no significant advances related to antimicrobial therapy for bacterial endocarditis. [11] . Recent reports on the use of daptomycin in Gram-positive bacteraemia and endocarditis are encouraging [12] . A randomised trial by Fowler et al. evaluating daptomycin compared with semi-synthetic penicillin and vancomycin for the treatment of endocarditis demonstrated no inferiority of daptomycin [8] . The endocarditis patients were primarily of right-sided and native valve types. There were very few left-sided endocarditis cases in the above trial and, using the definition applied in the study design, both daptomycin and the comparator fared poorly for leftsided endocarditis.
Using the data from this study, the cost-effectiveness of daptomycin was compared with that of vancomycin in combination with gentamicin in patients with MRSA bacteraemia with or without endocarditis. The results showed the similarity of daptomycin with vancomycin in combination with gentamicin [9] . Daptomycin is currently approved for the treatment of right-sided endocarditis. Our study comprised NVE as well as PVE, all of which were left-sided. PVE is associated with significantly higher mortality than NVE [1] . Additionally, the medical treatment of PVE is associated with a worse outcome [13] . Of the four cases of PVE in our series, three were successfully treated with daptomycin without undergoing surgery.
Increases in vancomycin MIC have been linked to increases in daptomycin MIC [14] . The clinical significance of such a finding is unknown, but they suggest awareness of such problems in a patient who fails to improve on daptomycin therapy and has a history of prior vancomycin use. We did not observe a lack of efficacy of daptomycin in either of the patients who received daptomycin subsequent to therapeutic failure with vancomycin.
Limitations of our report include the small number of patients. It is interesting to note that we had one isolate (S. mitis) which revealed resistance in spite of the absence of prior exposure to daptomycin. This highlights the risk of therapeutic failure even in the absence of prior exposure to daptomycin. There were three cases from whom the isolates were lost for daptomycin sensitivity (Table 2) . We observed the effectiveness of daptomycin in endocarditis cases, all of which were left-sided, complicated and associated with a wide range of organisms.
Conclusion
Daptomycin is an effective and well-tolerated agent in difficult-to-treat cases of left-sided infective endocarditis (IE) involving a wide a range of Gram-positive organisms. Further studies are needed to confirm our observation of the efficacy of daptomycin in complicated and left-sided IE.
